Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients

Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients

Abstract Background Detection of circulating ESR1 mutations is associated with acquired resistance to aromatase inhibitor (AI) in metastatic breast cancer. Until now, the presence of circulating ESR1 mutations at the end of adjuvant treatment by AI in early breast cancer had never been clearly estab...

Full description

Bibliographic Details
Main Authors: Violette Allouchery, Ludivine Beaussire, Anne Perdrix, David Sefrioui, Laetitia Augusto, Cécile Guillemet, Nasrin Sarafan-Vasseur, Frédéric Di Fiore, Florian Clatot
Format: Article
Language:English
Published: BMC 2018-05-01
Series:Breast Cancer Research
Subjects:
Early breast cancer
ESR1 mutation
Circulating tumor DNA
Aromatase inhibitor resistance
Digital PCR
Online Access:http://link.springer.com/article/10.1186/s13058-018-0968-0

Internet

http://link.springer.com/article/10.1186/s13058-018-0968-0

Similar Items